References
- Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681. doi:10.1182/blood-2016-01-690636
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
- Huff D, Fortin Ensign S, Ryan M, et al. Histiocytic sarcoma treated with pembrolizumab: a case report and literature review. J Immunother Precis Oncol; in press; 2023.
- Ungureanu IA, Cohen-Aubart F, Heritier S, et al. PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours. Histopathology. 2023;83(2):320–325. doi:10.1111/his.14909
- Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165. doi:10.1158/2159-8290.CD-15-0913
- Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567(7749):521–524. doi:10.1038/s41586-019-1012-y
- Zanwar S, Abeykoon JP, Dasari S, et al. Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer J. 2022;12(6):97. doi:10.1038/s41408-022-00693-7
- Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 2018;131(2):265–268. doi:10.1182/blood-2017-10-812495
- Gounder M, Desai V, Kuk D, et al. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. Eur J Cancer. 2015;51(16):2413–2422. doi:10.1016/j.ejca.2015.06.109
- Goyal G, Lau D, Nagle AM, et al. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood. 2019;133(14):1607–1610. doi:10.1182/blood-2018-12-893917
- Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005;36(3):215–225. doi:10.1038/sj.bmt.1705015
- Ratei R, Hummel M, Anagnostopoulos I, et al. Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans’ cell sarcoma: evidence for hematopoietic plasticity. Haematologica. 2010;95(9):1461–1466. doi:10.3324/haematol.2009.021212
- Zeidan A, Bolanos-Meade J, Kasamon Y, et al. Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013;54(3):655–657. doi:10.3109/10428194.2012.717082
- Vowels MR, White L, Lam-Po-Tang PR. Bone marrow transplantation for malignant histiocytosis. Bone Marrow Transplant. 1987;2:110.